Skip to main content

Yellow Fever

4
Pipeline Programs
6
Companies
11
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
7100%
+ 3 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
1
1
Yellow fever vaccinePhase 4Vaccine1 trial
Yellow Fever VaccinePhase 1/2Vaccine1 trial
Active Trials
NCT04269265Completed43Est. Oct 2023
NCT01290055Completed27Est. Oct 2024
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
17DPhase 1/21 trial
Active Trials
NCT05859490Recruiting35Est. Dec 2025
AstriVax Therapeutics
AstriVax TherapeuticsBelgium - Heverlee
1 program
1
AVX70120 low dose levelPhase 11 trial
Active Trials
NCT06998004Completed112Est. Jan 2026
Sanofi
SanofiPARIS, France
4 programs
Stamaril®N/A1 trial
Yellow fever vaccinePHASE_2Vaccine1 trial
Yellow fever vaccinePHASE_2Vaccine2 trials
Yellow fever vaccinePHASE_3Vaccine1 trial
Active Trials
NCT03541694Completed622Est. May 2018
NCT04942210Active Not Recruiting568Est. Jun 2027
NCT05011123Active Not Recruiting690Est. Apr 2027
+2 more trials
Biocorp
BiocorpFrance - Issoire
1 program
Immunity After Two Doses of Yellow Fever VaccineN/AVaccine1 trial
Active Trials
NCT02572518Completed440Est. Jul 2015
GE HealthCare
1 program
XRX-001 Inactivated yellow fever vaccinePHASE_1Vaccine1 trial
Active Trials
NCT00995865Completed60Est. Oct 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Allergy TherapeuticsYellow fever vaccine
SanofiYellow fever vaccine
SanofiYellow fever vaccine
SanofiYellow fever vaccine
Oregon Therapeutics17D
Allergy TherapeuticsYellow Fever Vaccine
AstriVax TherapeuticsAVX70120 low dose level
SanofiYellow fever vaccine
GE HealthCareXRX-001 Inactivated yellow fever vaccine
SanofiStamaril®
BiocorpImmunity After Two Doses of Yellow Fever Vaccine

Clinical Trials (11)

Total enrollment: 2,924 patients across 11 trials

NCT01290055Allergy TherapeuticsYellow fever vaccine

Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine

Start: Apr 2019Est. completion: Oct 202427 patients
Phase 4Completed
NCT07222059SanofiYellow fever vaccine

Phase 3 Single Arm, Open Study on vYF in Adults

Start: Oct 2025Est. completion: Dec 2025254 patients
Phase 3Completed
NCT05011123SanofiYellow fever vaccine

Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia

Start: Oct 2021Est. completion: Apr 2027690 patients
Phase 2Active Not Recruiting
NCT04942210SanofiYellow fever vaccine

Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA

Start: Jul 2021Est. completion: Jun 2027568 patients
Phase 2Active Not Recruiting
NCT05859490Oregon Therapeutics17D

Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination

Start: Aug 2023Est. completion: Dec 202535 patients
Phase 1/2Recruiting
NCT04269265Allergy TherapeuticsYellow Fever Vaccine

The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination

Start: Jul 2020Est. completion: Oct 202343 patients
Phase 1/2Completed
NCT06998004AstriVax TherapeuticsAVX70120 low dose level

A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults

Start: Jun 2024Est. completion: Jan 2026112 patients
Phase 1Completed
NCT04142086SanofiYellow fever vaccine

Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults

Start: Jan 2020Est. completion: Jun 202173 patients
Phase 1Completed
NCT00995865GE HealthCareXRX-001 Inactivated yellow fever vaccine

Trial of Yellow Fever Inactivated Vaccine

Start: Jan 2010Est. completion: Oct 201060 patients
Phase 1Completed
NCT03541694SanofiStamaril®

Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea

Start: Apr 2018Est. completion: May 2018622 patients
N/ACompleted
NCT02572518BiocorpImmunity After Two Doses of Yellow Fever Vaccine

Immunity After Two Doses of Yellow Fever Vaccine

Start: May 2014Est. completion: Jul 2015440 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 2,924 patients
Vaccine is the dominant modality (100% of programs)
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.